Lilly - TechWire

Lilly

2025.03.05

16:17

Alzheimer's disease treatment costs are high, Eli Lilly calls for innovative drugs targeting the cause of the disease to be included in medical insurance

At this year's Two Sessions, the issue of population aging was put on the agenda. The government is working to address the challenges posed by rapid aging to the economy and society, and is expected to introduce more measures to improve the well-being of the elderly. This also allows multinational medical companies that are actively developing health industries in China to see huge market potential. Recently, Huzur Devletsah, President and General Manager of Eli Lilly China, called in an exclusive interview that innovative drugs that are used in the early stages of Alzheimer's disease, target the causes, and can significantly slow the progression of the disease should be included in medical insurance as soon as possible to improve accessibility and affordability for patients. Achieving Early Intervention of Alzheimer's Disease Tehran said that Eli Lilly's vision is to ultimately achieve early intervention of Alzheimer's disease in the next 10 years through timely testing, accurate diagnosis and appropriate treatment.

2025.02.26

23:06

Eli Lilly plans to build four new factories in the United States this year, with an investment of more than $27 billion

Eli Lilly announced plans to build four new plants in the United States this year, three of which will focus on the production of active pharmaceutical ingredients (API) and further strengthen the supply chain, and another plant will focus on future injectable therapies. Eli Lilly expects the new plant to create more than 3,000 highly skilled jobs, including engineers, scientists, operators and laboratory technicians. In addition, the company expects to create nearly 10,000 construction jobs during the development of the plant. Eli Lilly expects the new plant to be put into production within 5 years. From 2020 to 2024, Eli Lilly's total capital commitment in the United States is US$23 billion, and the new plant project will bring this figure to more than US$50 billion.

18:23

Eli Lilly cuts U.S. weight-loss drug prices

Eli Lilly announced in the US market that it would reduce the price of the small bottle of Zepbound (Telpotide for Weight Loss). Specifically, Eli Lilly will reduce the monthly cost of the 2.5 mg and 5 mg small bottle of Zepbound to $349 and $499 respectively. After this price reduction, the monthly cost of both doses of the drug will be reduced by $50.

2025.02.25

21:19

Eli Lilly cuts $50 off small bottles of its popular diet drug Zepbound

Eli Lilly announced that the monthly price of the popular weight loss drug Zepbound 2.5 mg and 5 mg vials will be reduced to $349 and $499 respectively, a reduction of about $50 from the previous price. In addition, Eli Lilly also launched a 10 mg vial of Zepbound, with a monthly price of $499. Eli Lilly executives said that since Zepbound was launched, more than 10% of patients have started taking low-dose Zepbound.

20:13

Eli Lilly's US stock rose more than 2% before the market opened

Eli Lilly's U.S. stocks rose more than 2% in pre-market trading as the company launched a high-dose weight loss drug.

08:19

Huatai Securities: There is a large gap in global GLP-1 products, and the M&A wave is expected to continue

Huatai Securities believes that GLP-1 has shown great market potential, and currently only Novo Nordisk and Eli Lilly are the leading MNCs in sales overseas, but they have not yet formed a complete product matrix. Other MNC products are still in the clinical stage, the competition landscape has not yet been finalized, and there is a large gap in products. Since 2004, there have been frequent overseas transactions of domestic GLP-1. We believe that the competitiveness of domestic GLP-1 products is not inferior to that of overseas products. Among them, there are many high-quality assets with leading clinical progress in targets such as GLP-1 oral small molecules, GLP-1/GIP, GLP-1/GIP/GCGR, GLP-1/GCGR/FGF21, and ActRII, which are expected to enter the global market with the help of BD in the future.

2025.02.22

08:13

Trump warns pharmaceutical companies: Tariffs are coming, so they should speed up the transfer of overseas production to the United States

On February 21, local time, CCTV reporters learned that according to informed sources, US President Trump warned pharmaceutical companies in a private meeting that tariffs were coming and said that these companies should speed up the pace of transferring overseas production to the United States. It is reported that Trump met with several pharmaceutical industry executives at the White House on the 20th, including the CEOs of Eli Lilly, Merck and Pfizer.

2025.02.06

23:17

Eli Lilly executive: Zepbound, a weight loss drug, is performing very well in the U.S. market

Eli Lilly executive: Weight loss drug Zepbound is performing very well in the U.S. market.

23:14

Eli Lilly (LLY.N) executives: Weight loss drug Zepbound is performing very well in the U.S. market.

19:49

Eli Lilly (LLY.N): Still expects revenue to be between $58 billion and $61 billion in 2025, while the market forecast is $59.41 billion.

2025.01.22

22:20

Jefferies: Raised Eli Lilly (LLY.N) price target from $996 to $1,020.

2025.01.15

05:02

Eli Lilly (LLY.N) closed down 6.6%, its biggest one-day drop since March 2021.

2025.01.14

22:42

Eli Lilly (LLY.N) fell 5%, its biggest intraday drop since November 15.

22:42

Eli Lilly's decline widened to 5%, the biggest intraday drop since November 15

Eli Lilly's losses widened to 5%, its biggest intraday drop since November 15.

22:35

Eli Lilly (LLY.N) fell 2.6 percent as it forecast weak fourth-quarter sales of its diet pills.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Intel's US stock rose more than 10% in the night trading
                            2025-03-12

                                    360 launches DS large model security solution to protect the development of DeepSeek
                            2025-03-12

                                    JD.com's revenue in Q4 2024 is expected to be 347 billion yuan
                            2025-03-06

                                    Daiwa Securities raised Alibaba Group's target price from HK$165 to HK$175
                            2025-03-07

                                    Ouye Semiconductor completed B2 round of financing of hundreds of millions of yuan to promote large-scale application of products
                            2025-03-13